![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change](https://a.storyblok.com/f/176343/1920x1080/0234c60f2d/home-teaser.jpg)
glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change
EUR23.52
EUR56.52
Pay in 4 interest-free payments of $5.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3845421588413440068)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change](https://www.reuters.com/resizer/v2/F33QVZHAVJKINCYYAWNRZGPP2I.jpg?auth=2bf5c4f15a6a09c7e4a68854c7ccf2ea81d0ea0834b9192fb9d93fb1cd369b7a)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change](https://pharmaphorum.com/sites/default/files/styles/x_large/public/2023-10/Roche_logo.jpg?itok=-fpSgFk6){kind=logo}
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity #LaRochePosayPartner GLP-1 medications can change](https://static.seekingalpha.com/uploads/2026/1/28/59327344-17695975198584123_origin.png)
